Login to Your Account



Celltech Misses Main Endpoint In Phase III Crohn's Disease Trial

By Nuala Moran


Wednesday, August 7, 2002
LONDON - Celltech Group plc failed to reach the primary endpoint in Phase III trials of CDP 571, a humanized antibody for the treatment of Crohn's disease, leaving the future of the compound hanging on discussions with regulators to see if approval can be granted for the management of disease flares.(BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription